Evercore ISI Initiates Coverage on Apellis Pharmaceuticals (APLS)

Analysts at Evercore ISI started coverage on shares of Apellis Pharmaceuticals (NASDAQ:APLS) in a research note issued to investors on Monday, MarketBeat.com reports. The brokerage set an “outperform” rating on the stock.

A number of other research firms also recently weighed in on APLS. Citigroup began coverage on shares of Apellis Pharmaceuticals in a research report on Monday. They set a “buy” rating and a $23.00 target price for the company. J P Morgan Chase & Co began coverage on shares of Apellis Pharmaceuticals in a research report on Monday. They set an “overweight” rating and a $31.00 target price for the company.

Shares of Apellis Pharmaceuticals (NASDAQ:APLS) opened at $13.73 on Monday. Apellis Pharmaceuticals has a 52-week low of $12.45 and a 52-week high of $15.41.

In related news, major shareholder Global Strategic Fund I. Venbio bought 127,515 shares of Apellis Pharmaceuticals stock in a transaction dated Monday, November 13th. The stock was purchased at an average cost of $14.00 per share, with a total value of $1,785,210.00. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website.

ILLEGAL ACTIVITY WARNING: “Evercore ISI Initiates Coverage on Apellis Pharmaceuticals (APLS)” was first reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this article on another site, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The correct version of this article can be viewed at https://www.com-unik.info/2017/12/05/apellis-pharmaceuticals-apls-coverage-initiated-by-analysts-at-evercore-isi.html.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The Company’s lead compounds are designed to inhibit complement component 3 (C3), the central protein in the complement cascade.

What are top analysts saying about Apellis Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Apellis Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit